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Crystal structure of a viral cyclin, a positive regulator of 
cyclin-dependent kinase 6
Ursula Schulze-Gahmen1*, Jae U Jung2 and Sung-Hou Kim1
Background: Cyclin-dependent kinases (CDKs) have a central role in cell-cycle
control and are activated by complex formation with positive regulatory proteins
called cyclins and by phosphorylation. The overexpression and mutation of
cyclins and CDKs has been associated with tumorigenesis and oncogenesis. A
virus-encoded cyclin (v-cyclin) from herpesvirus saimiri has been shown to
exhibit highest sequence homology to type D cyclins and specifically activates
CDK6 of host cells to a very high degree. 
Results: We have determined the first X-ray structure of a v-cyclin to 3.0 Å
resolution. The structure of the core domains is very similar to those of cyclin A
and cyclin H from human cells. To understand the structural basis for the 
v-cyclin specificity for CDK6 and the insensitivity of the complex to inhibitors of
the p21 and INK4 families, a v-cyclin–CDK2 model was built on the basis of the
known structures of human cyclin A in complex with CDK2 and the CDK
inhibitor p27Kip1.
Conclusions: Although many critical interactions between cyclin A and CDK2
would be conserved in a v-cyclin–CDK2 complex, some appear sterically or
electrostatically unfavorable due to shifts in the backbone conformation or
sidechain differences and may contribute to v-cyclin selectivity for CDK6. The
insensitivity of v-cyclin–CDK6 complexes to inhibitors of the p21 family is
probably due to structural changes in v-cyclin that lead to a flatter surface area
offering fewer potential contacts with the protein inhibitor. In addition, sequence
changes in v-cyclin eliminate hydrogen-bonding partners for atoms of the
p27Kip1 inhibitor. This structure provides the first model for interactions between
v-cyclins and host cell-cycle proteins; these interactions may be important for
virus survival as well as oncogenic transformation of host cells.
Introduction
The major transitions of the eucaryotic cell cycle are con-
trolled by cyclin-dependent kinases (CDKs) [1–4] that
exert their regulatory function through the phosphoryla-
tion of key proteins involved in cell-cycle transitions, such
as the retinoblastoma gene product [5]. To ensure proper
timing and coordination of cell-cycle events, kinase activ-
ity is tightly controlled by several mechanisms [6]. Eucary-
otic cells express different isoforms of CDKs that become
activated at different stages of the cell cycle or that are
expressed in a cell type specific manner. All CDK apo-
enzymes are inactive and require complex formation with
regulatory cyclin subunits. Cyclins are members of a
family of structurally related proteins that bind and acti-
vate CDK catalytic subunits. CDK–cyclin interactions are
quite specific in that different CDK isoenzymes preferen-
tially form complexes with specific types of cyclin sub-
units. In somatic cells and yeast, additional regulatory
mechanisms of CDK activity have evolved to ensure that
the initiation of cell-cycle events is delayed when growth
conditions are suboptimal or when preparations for the
next cell cycle are incomplete. In addition to cyclin
binding, maximum CDK activation requires phosphoryla-
tion of a conserved threonine residue by a CDK-activating
kinase [7–11]. The activated CDK–cyclin complex can be
inhibited by phosphorylation of a conserved threonine/tyro-
sine pair or by complex formation with CDK inhibitors of
the p21 family, comprising p21Cip1/WAF1, p27Kip1 and
p57Kip2, and of the INK4 family, which includes p15, p16,
p18 and p19 [12,13].
Neoplastic diseases are characterized by uncoordinated cell
growth. Not surprisingly, mutations and overexpression of
cyclins and CDKs, especially cyclin D1 and CDK4, have
been connected to tumorigenesis [14–16]. The D-type
cyclins, which bind to CDK4 and CDK6, are linked to the
regulation of the restriction point in mammalian cells in
late G1 phase of the cell cycle [16] at which the cell
commits itself to another round of DNA replication and
cell division. Hence, overexpression of cyclin D may con-
tribute to oncogenesis. In addition, loss or mutation of
CDK inhibitors has been frequently observed in certain
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tumors. In particular, inhibitors of the INK4 family appear
to function as tumor suppressors [17,18].
Recently, two viral proteins with homology to mam-
malian cyclins have been identified in oncogenic gamma-
herpesvirus saimiri (HVS) [19,20] and Kaposi’s sarcoma
associated herpesvirus (KSHV) [21–23]. Both proteins
show highest homology to D-type cyclins and associate
with CDK6, resulting in strong in vitro kinase activity
towards retinoblastoma protein and histone H1. This
high level of unlicensed CDK activity most likely causes
the deregulation of cell proliferation inherent to HVS and
KSHV diseases. 
We report here the first X-ray structure of a viral cyclin 
(v-cyclin) from HVS. This structure will help us to under-
stand the peculiar characteristics of v-cyclins, such as the
strong preference of v-cyclin for CDK6 over other CDKs,
and the insensitivity of v-cyclin–CDK complexes to CDK
inhibitors of the p21 and INK4 families. The v-cyclin
structure is compared with the three-dimensional struc-
tures of cyclin A [24,25] and cyclin H [26], and models of
v-cyclin–CDK complexes are built on the basis of the
homologous structures of cyclin A in complex with CDK2
[24] or p27Kip1 [27].
Results and discussion
Structure determination
v-Cyclin crystallizes in space group P212121 with cell
dimensions a = 37.92 Å, b = 61.44 Å, c = 130.57 Å. The
crystals diffract to 3.0 Å resolution with a rapid decrease in
diffraction intensity between 4.0 and 3.0 Å resolution,
indicative of a high temperature factor of 60–70 Å2 for the
diffraction data (Table 1). The structure was solved by a
combination of molecular replacement and multiple iso-
morphous replacement (MIR). The three structures used
as models for molecular replacement, bovine cyclin A [25],
human cyclin A from the cyclin-A–CDK complex [24] and
cyclin H [26], have sequence identities with v-cyclin of
less than 20% and sequence similarities of less than 40%
(Figure 1). For molecular replacement, the models were
reduced to the core cyclin fold, consisting of two homolo-
gous domains (I and II). Domain I contains the cyclin box,
which is a region of approximately 100 amino acid residues
that is conserved among all cyclins isolated to date. Mol-
ecular replacement using EPMR (evolutionary program-
ming for molecular replacement) [28] with 15.0–4.0 Å data
identified the same orientation and translation for the
bovine cyclin A and human cyclin A models as the best
solution according to the highest correlation coefficient.
The best model included residues 207–400 of cyclin A
with non-identical residues replaced by alanine or glycine;
two larger loop regions comprising residues 244–250 and
343–351 were deleted in the model. Molecular replace-
ment solutions for the whole model or its two separate
domains were almost identical, indicating that the domain
orientation in v-cyclin is similar to that in cyclin A. Rigid-
body refinement of the initial model in three segments,
residues 207–243, 251–342 and 352–400, using data from
10.0–3.5 Å gave an R value of 42.2%. The model was ini-
tially refined with the program X-PLOR 3.84 [29] using
only positional refinement. Electron-density maps were
calculated using the CCP4 suite of programs [30] with
SIGMAA-weighted combined phases from molecular
replacement and MIR, followed by density modification
with the program DM [30] using solvent flattening and
histogram matching. These maps showed clear density for
the omitted N-terminal helix (residues 23–30) and indi-
cated that the helix is in a similar orientation to that in
human cyclin A. In addition, many of the sidechains in
domain I could be clearly identified and built into the
model. However, the density for domain II, residues
150–254, remained poor, even after several cycles of
manual rebuilding and refinement in X-PLOR 3.84. The
model improved significantly after switching to refine-
ment using a developmental version of the program CNS
(AT Brünger, personal communication) with a maximum
likelihood target function [31,32], anisotropic B-factor cor-
rection, flat bulk-solvent correction, and inclusion of low-
resolution data to 20 Å. Electron-density maps calculated
from models after simulated annealing by torsion angle
molecular dynamics with maximum likelihood target
showed less model bias aiding in the manual rebuilding of
the model. In the final structure, the N-terminal His-tag,
residues 1–21 and the C-terminal residues 251–254 are dis-
ordered. In addition, 25 residues between residues 22 and
225 and most of the residues between 227 and 250 were
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Table 1
Data collection, processing and phasing statistics.
Data sets Native data* EMTSA (CH3)HgI 
Resolution range (Å) 25–3.0 25–4.0 25–4.0
Measured reflections 23,083 7005 7156
Unique reflections 6501 2576 2550
Completeness (%)† 98.9 (99.8) 90.1 (70.4) 89.4 (82.6)
Rsym‡ 9.5 (35.0) 9.0 (29.0) 7.0 (22.3)
I/σI 11.5 (2.8) 9.6 (3.6) 13.3 (5.0)
Riso§ 24.0 27.0
Phasing power#
(centric/acentric) 1.0/0.7 1.3/0.8
Rcullis¶
(centric/acentric) 0.78/0.79 0.75/0.73
Number of sites 1¥ 3
Figure of merit 
(centric/acentric) 0.59/0.40
*Collected at the Brookhaven National Synchrotron Light Source.
†Numbers in parentheses are for the highest resolution shell.
‡Rsym = ΣhklΣi |I–<I>|/ΣhklΣi. §Riso = Σhkl |FPH–FP|/ Σhkl |FP|. #Phasing
power F(H)/E, is the root mean square heavy-atom structure-factor
amplitudes divided by the lack of closure error.
¶Rcullis = Σ |FPH ± FP|–|Fhcalc|/Σ |FPH–FP|. ¥The heavy-atom site in the
ethyl mercuri thiosalicyclic acid (EMTSA) derivative is the same as one
of the sites in the CH3HgI derivative.
truncated to alanine because of missing sidechain densities
(Figure 1). Residues presumed to be important for
complex formation with CDK [24] have well defined elec-
tron density (Figure 2), however, allowing the discussion
of the structure/function relationship for this v-cyclin. The
structure shows good model geometry (Table 2), including
>80% of the mainchain phi–psi angles in the most favored
regions of the Ramachandran plot and no residues in disal-
lowed regions, as defined by PROCHECK [33]. The
structure also adequately accounts for the observed diffrac-
tion data, with an Rfree value of 32.4% (Table 2).
Overall structure of v-cyclin and comparison with cyclin A
and cyclin H
The X-ray structure of HVS v-cyclin shows the typical
cyclin fold, as described for cyclin A [24,25] and cyclin H
[26], and consists of two core domains each containing five
helices (Figure 3a). Outside the core domains, an addi-
tional N-terminal helix and C-terminal loop show no
sequence homology to other cyclin structures. The two
core domains (comprising residues 48–144 and 150–243)
can be superimposed with a root mean square deviation
(rmsd) of 0.53 Å for 28 equivalent Cα atoms [34] and an
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Figure 1
Amino acid sequence alignment based on the
three-dimensional structures of v-cyclin,
human cyclin A and human cyclin H. The 
N- and C-terminal alignments in parentheses
are arbitrary. The degree of sequence
conservation is indicated below the alignment:
identical residues in all three proteins are
marked by an asterisk; residues with high
similarity by a colon; and residues with low
similarity by a single dot. v-Cyclin helical
elements are indicated as boxes above the
sequence and labeled H1–H5 and H1′–H5′
in domains I and II, respectively. Secondary
structure elements were defined according to
criteria published by Kabsch and Sander [49].
Amino acid residues with missing sidechain
density are underlined, residues with
presumed contacts to CDK are in bold, and
residues involved in crystal contacts are
marked with filled triangles. 
                                               
V-cyc                 (MADSPNRLNRAKIDSTTMKDPRVLNNLKLRELLLPKFTSLWEI)   43
Cyc A                 (MSIVLEDEKPVSVNEVPDYHEDIHTYLREMEVKCKPKVGYMKK)  202
Cyc H        (MYHNSSQKRHWTFSSEEQLARLRADANRKFRCKAVANGKVLPNDPVFLEPHE)   52
V-cyc    QTEVTVDNRTILLTWMHLLCESFELDKSVFPLSVSILDRYLCKKQGTKKTLQKIGAAC  101
Cyc A    QPDITNSMRAILVDWLVEVGEEYKLQNETLHLAVNYIDRFLSSMSVLRGKLQLVGTAA  260
Cyc H    EMTLCKYYEKRLLEFCSVFKP--AMPRSVVGTACMYFKRFYLNNSVMEYHPRIIMLTC  108
         :  :    .  *: :   . .   : ....  :   :.*:  . .  .   : :  :.
         
V-cyc    VLIGSKIRTVKPMTVSKLTYLSCDCF-----TNLELINQEKDILEALKWDTEAVLATD  154
Cyc A    MLLASKFEEIYPPEVAEFVYITDDTY-----TKKQVLRMEHLVLKVLTFDLAAPTVNQ  313
Cyc H    AFLACKVDEFN-VSSPQFVGNLRESPLGQEKALEQILEYELLLIQQLNFHLIVHNPYR  165
     ::..*.  .     .::.    :       :  :::. *  ::: *.:.  .     
V-cyc    FLIPLCNALKIPED---LWPQLYEAASTTICKALIQ-PNIALLSPGLICAGGLLTTIE  208
Cyc A    FLTQYFLH-QQPA----N-CKVESLAMFLGELSLIDADPYLKYLPSVIAGAAFHLALY  366
Cyc H    PFEGFLIDLKTRYPILENPEILRKTADDFLNRIALT-DAYLLYTPSQIALTAILSSAS  222
          :       :           : . *        :         *. *.  .:  :          
         
V-cyc    TDNTNCRPWTCYLEDLSSI-------LNFSTNTVRTVKDQVSEA(FSLYDLEIL)     254
Cyc A    TVTG-QS-WPESLIRKTGY-------LESLKPCLMDLHQTYLKA(PQHAQQSIR)     410
Cyc H    RAGI-TM---ESYLSESLMLKENRTCLSQLLDIMKSMRNLVKKY(EPPRSEEVA)     271
                     :   .         *.     :  :::   :  
HN
H1 H2 H3
H4 H5
H1' H2' H3'
H4' H5'
1
1
160
Structure
Figure 2
Electron density for several conserved
residues in the presumed v-cyclin–CDK
interface. The electron-density map at 3.0 Å
was calculated with SIGMAA-weighted
coefficients (2Fo–Fc) and model phases αc
from the refined model; the map is contoured
at 1.2σ.
104 I104 I
136 E 136 E
145 W 145 W
140 L140 L
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rmsd of 1.25 Å for 37 Cα atoms that are located in helices
H2, H3, H5 and H2′, H3′, H5′, respectively (where a
prime is used to designate structural elements of the
second domain). The two domains are related by a 171.5°
rotation and a 14 Å translation about an axis perpendicular
to the plane of Figure 3a, positioned approximately
between helices H2 and H2′. 
Although the sequence homologies between v-cyclin and
cyclins A and H are low (with 21% or 9% sequence iden-
tity, respectively, for the cyclin fold; Figure 1), the struc-
tures are similar. The overall structure of v-cyclin shows
more homology to cyclin A than to cyclin H because their
relative domain orientations are similar and even the 
N-terminal helix outside the core cyclin fold shows a
similar orientation (Figure 3b). In contrast, cyclin H has a
slightly different domain orientation, and structural
elements outside the cyclin fold vary considerably
(Figure 3b). However, a superposition of the separate 
v-cyclin domains onto cyclin A and cyclin H results in an
rmsd of 0.76 Å for 71 equivalent Cα atoms in domain I of
cyclin A and an rmsd of 0.90 Å for 52 equivalent Cα atoms
in domain I of cyclin H. The rmsd values for domain II are
higher with 1.08 Å for 45 equivalent Cα atoms for cyclin A
and 1.09 Å for 44 equivalent Cα atoms for cyclin H. These
values reflect the better sequence and structural conserva-
tion of the cyclin box domain [35], which provides most of
the contact residues for complex formation between
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Table 2
Refinement statistics.
Resolution (Å) 20.0–3.0
Rcryst (%)* 24.2
Rfree (%)† 32.4
B factor (overall) (Å2) 64.6
Model geometry
Rmsd from ideality
bonds (Å) 0.008
angles (°) 1.52
Ramachandran plot quality‡
most favored (%) 81.8
additionally allowed (%) 17.5
generously allowed (%) 1.4
disallowed (%) 0.0
*Rcryst = Σh||Fobs(h)|–|Fc(h)||/ Σh|Fobs(h)|, where Fobs and Fc are the
observed and calculated structure-factor amplitudes for the reflection
with Miller indices h = (h,k,l) and Fobs ≥ 2σ. †A randomly selected 10% of
structure-factor amplitudes with Fobs ≥ 2σ were excluded from the
refinement and used to compute Rfree. ‡As defined in PROCHECK [33].
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The overall fold of v-cyclin. (a) Schematic drawing of v-cyclin. Domain I
is colored purple, domain II blue and N-terminal and C-terminal
extensions are in cyan. Domains I and II are related by a pseudo-
twofold rotation axis, which is perpendicular to the plane of the paper
and located approximately between helices H2 and H2′. Helices in the
two conserved core domains are labeled H1 to H5 and H1′ to H5′,
respectively. The N-terminal helix outside the conserved core is labeled
HN. (b) Stereoview Cα trace of superimposed v-cyclin (blue), cyclin A
(green) and cyclin H (pink). Every twentieth residue in v-cyclin is
labeled with its residue number. The molecules were superimposed on
domain I, located at the top of the figure. Due to different relative
domain orientations, the structures diverge more in domain II, at the
bottom of the figure. In addition, N-terminal and C-terminal extensions
of the core cyclin fold in cyclins A and H and insertions in cyclin H
have very little or no structural homology with v-cyclin. (The figure was
generated using the program INSIGHT II.)
cyclin A and CDK2 [24]. Cyclin molecules provide a good
example of highly conserved three-dimensional structures
with very low sequence homologies. The similarity
between v-cyclin and cyclin A allows a functional analysis
of the v-cyclin structure based on the three-dimensional
structure of the cyclin-A–CDK2 complex. 
Analysis of the crystal packing reveals that several
residues, presumed to be important for complex formation
with CDK, are also involved in crystal contacts (Figure 1).
It appears as though crystal contacts of the v-cyclin
residues Lys107, Ile108, Pro113 and Trp145 substitute for
contacts with CDK as is shown when CDK2 is super-
imposed onto the v-cyclin crystal contact interface
(Figure 4). These crystal contacts need to be considered
in the discussion of potential v-cyclin–CDK interactions.
Structural basis for the selectivity of v-cyclin–CDK complex
formation 
HVS v-cyclin shows highest sequence homology to D-type
cyclins, with human cyclin D3 having a sequence identity
of 29.5% in 237 residues after sequence alignment using
the program SIM [36]. Unlike D-type cyclins, however, 
v-cyclin only forms stable complexes with CDK6. These
complexes exhibit higher specific kinase activity [20] and
are not regulated by CDK inhibitors of the INK4 or p21
families [37]. In order to analyze the structural basis for
these functional differences, a model for the active 
v-cyclin–CDK6 complex is required. Because CDK2 in
complex with cyclin A is in the activated conformation, it
is probably a better model for a v-cyclin–kinase complex
than the recently determined structures of CDK6 in
complex with p16INK4a or p19INK4d [38,39], which show
none of the activating structural changes caused by cyclin
binding. Instead, CDK6 in complex with INK4 inhibitors
has structural distortions that move it further away from
the active structure. For this reason, we superimposed the
v-cyclin structure onto the X-ray structure of the unphos-
phorylated active cyclin-A–CDK2 complex. The buried
surface areas in the v-cyclin–CDK2 model complex cover
1190 Å2 in CDK2 and 1080 Å2 in v-cyclin. These areas are
very similar in distribution and size to those for the
cyclin-A–CDK2 complex, except that no contacts are
observed between v-cyclin and the C-terminal lobe of
CDK2. In the cyclin-A–CDK2 complex, these contacts
are mediated by residues in the N-terminal helix of cyclin
A. The missing contacts in v-cyclin might be due to disor-
dered sidechains in the N-terminal helix of v-cyclin. The
buried surface of CDK2 is mainly formed by residues
from four regions: the PSTAIRE helix (a conserved and
characteristic feature for all CDKs); β strand 4; the C-ter-
minal end of helix 3; and the T loop [40]. The contact
surface on v-cyclin is formed by residues in the N-termi-
nal helix, at the C-terminal end of helix H3 and the fol-
lowing loop, helix H5 and the connecting strand to the
second domain of v-cyclin.
Among the v-cyclin–CDK2 contacts, some are well con-
served compared with cyclin-A–CDK2 contacts, whereas
others are less conserved and sterically or electrostatically
unfavorable. Hydrogen bonds between the sidechains of
v-cyclin residues Lys107 and Glu136 and the backbone of
residues Glu42 to Val44 in CDK2 (Figure 5a) are well con-
served. The CDK2 residues 42 to 44 are located just
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Figure 4
Stereoview drawing of the crystal contacts in
v-cyclin crystals in comparison with CDK2
contacts. v-Cyclin is drawn in blue, symmetry-
related molecules are in green and CDK2 is
depicted in red. The location of the symmetry-
related molecules is close to that of CDK2
areas interacting with v-cyclin in a 
v-cyclin–CDK2 model complex.
R50R50
I108I108
S117S117
T128T128
W145 W145
I49I49
K118 K118
K107K107 S46S46
P113P113
Y121Y121
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N-terminal of the PSTAIRE helix. The interface between
v-cyclin and the PSTAIRE helix itself includes some
unfavorably close contacts. The backbone of residues in
the loop between helices H3 and H4 and in H4 shows a
larger difference from cyclin A then the average rmsd for
domain I. This backbone shift causes many very close
contacts between residues 108 to 113 in v-cyclin and
residues in the PSTAIRE helix and T loop (Figure 5b).
The T loop was observed in different conformations in
the CDK2 apoenzyme, unphosphorylated and phosphory-
lated cyclin-A–CDK2 complex, and in the CDK6–p16INK4
complex [38], therefore, the v-cyclin–CDK2 model might
not be valid for the T loop region. However, close contacts
between v-cyclin and the PSTAIRE helix, especially
between Pro113 in v-cyclin and Ser46 in CDK2, would
prohibit complex formation with CDK2 unless conforma-
tional changes are induced. As v-cyclin residues Lys107,
Ile108 and Pro113 are involved in a small number of
crystal contacts, they may have slightly different confor-
mations in the free protein that could allow more favorable
contacts with CDK2. The sequence change to PLSTIRE
in CDK6 (Figure 6) might cause structural differences
from CDK2 that could allow more favorable interactions
between v-cyclin and CDK6.
The residue with the largest buried surface in the 
v-cyclin–CDK2 model interface is Trp145 of v-cyclin
(96 Å2), which interacts with His71 in CDK2 (59 Å2) with
many unfavorably close interactions. A comparison with
the equivalent cyclin-A–CDK2 interface (Figure 5c)
reveals a 1.5–2.0 Å shift of Trp145 relative to the corre-
sponding Phe304 in cyclin A. As the area is otherwise
structurally well conserved, the shift is most likely
induced by extensive crystal contact involvement of
Trp145 (Figures 1 and 4). If Trp145 were placed in the
equivalent position to Phe304 in cyclin A, the unfavorable
contacts with His71 would be relieved and instead
hydrophobic contacts with Ile52 and Val69 would be pos-
sible. The sequence conservation of Trp145 in all D-type
cyclins and its homologous replacement by Phe304 in
cyclin A indicates an important function for this residue in
complex formation with all CDKs [24].
Sequence differences between v-cyclin and D-type cyclins
at positions Arg30 and Glu148 may contribute to their dif-
ferent CDK selectivity; Arg30 is replaced by glutamic acid
in all D-type cyclins and Glu148 by alanine. These two
residues are close together in the native protein and are
also close to the charged residues Arg122 and Glu57 in a
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Figure 5
Schematic drawing of the molecular contacts
between v-cyclin and CDK2 in a model
complex based on the cyclin-A–CDK2
complex. v-Cyclin is shown in blue, CDK2 in
orange and cyclin A in green. (a) The
conserved hydrogen bonds between Glu136
and Lys107 in v-cyclin and the backbone
atoms of residues 42–44 in CDK2. The
sidechains of residues 42–44 are omitted for
clarity. Conserved hydrogen bonds are
indicated as broken lines. The dotted line
indicates a contact that is too long for a
hydrogen bond in the v-cyclin–CDK2
complex, but could probably be formed after
minor structural changes in either molecule.
(b) Schematic drawing of the close
interactions between residues 111–113 in 
v-cyclin and residues 46–50 in the PSTAIRE
helix of CDK2, the T loop residues 159–162
and Arg150. The backbone structure of cyclin
A is shown for comparison. (c) Potential
contact residues for the v-cyclin residue
Trp145. Too close contacts with His71 in
CDK2 are probably caused by a shift in the
Trp145 position due to crystal contacts. If
Trp145 is overlapped onto the equivalent
Phe304 in cyclin A, more favorable
interactions with Ile52 and Val69 in CDK2
can be formed. (d) A patch of closely
positioned charged residues in a modeled v-
cyclin–CDK2 complex. In particular, residues
Arg30 in v-cyclin and Arg122 in CDK2 are in
too close contact. (The figures were made
using the program MOLSCRIPT [50].)
modeled v-cyclin–CDK2 complex (Figure 5d), leading to
many electrostatically unfavorable interactions. In con-
trast, the equivalent amino acid residues in D-type cyclins
appear energetically more favorable for complex forma-
tion with CDK2. A replacement of Glu57 in CDK2 by
His67 together with a three residue insertion in CDK6
may also provide a better fit between v-cyclin and CDK6.
In summary, the model of a v-cyclin–CDK complex based
on the structure of the cyclin-A–CDK2 complex shows
many conserved interactions between v-cyclin residues
and the loop preceding the PSTAIRE helix, the
PSTAIRE helix itself, and residues 69–72 of CDK2.
Some unfavorably close contacts between the PSTAIRE
helix and v-cyclin residues 107–113, as well as contacts
between charged residues Arg30 and Glu148 in v-cyclin
and Arg122 and Glu57 in CDK2, may contribute to 
v-cyclin specificity for CDK6. However, as in both cases
the respective v-cyclin residues are also involved in, or
close to, crystal contacts, a clear evaluation of their contri-
bution to complex formation is difficult.
The insensitivity of v-cyclin–CDK6 to p27Kip1 and p16INK4 
The p27Kip1 kinase inhibitor (henceforth p27) [41,42] asso-
ciates with and inhibits cyclin–CDK complexes with
broad preference for the G1 and S phase kinase com-
plexes. However, it does not bind to or inhibit complexes
with v-cyclin [37]. In the p27–cyclin-A–CDK2 ternary
complex [27], p27 interacts with both CDK2 and cyclin A.
A ten amino acid long rigid coil in p27 (residues 25–35)
binds in a shallow groove on cyclin A in a partially
extended conformation. The peptide-binding groove on
cyclin A is formed by helices H1, H3 and H4 of the cyclin-
box repeat, and is lined with highly conserved amino
acids. The corresponding site on v-cyclin appears as a
much wider groove, due to backbone changes in helix H4
and the following loop which includes residues 120 to 128
(Figure 7). Although high temperature factors in this loop
indicate flexibility, structural differences from cyclin A are
quite large and will provide fewer van der Waals contacts
between v-cyclin residues and p27. In addition, of the
seven intermolecular hydrogen bonds observed between
the p27 coil and cyclin A [27], only three could possibly be
formed in a complex with v-cyclin due to the described
conformational changes and sequence differences. In
cyclin A, Glu220 forms a hydrogen bond with Ser27 and a
salt bridge with Arg30 of p27; this residue is conserved in
cyclins A, E and D, but replaced by a leucine residue in 
v-cyclin. Hence, conformational differences that affect the
shape of the p27-binding pocket, as well as sequence dif-
ferences that remove hydrogen bond atom partners may
contribute to a reduced binding affinity of p27 to 
v-cyclin–CDK6 complexes.
The X-ray structures of the p16INK4–CDK6 and
p19INK4–CDK6 complexes [38,39] revealed that the
inhibitors bind to one side of the catalytic cleft, opposite
where cyclin would bind, and interact with both lobes of
CDK6. The inhibitors prevent or reduce cyclin binding by
causing structural changes that propagate to the cyclin-
binding site. Ternary complexes of CDK6, cyclin and
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Figure 6
Amino acid sequence alignment of human
CDK2, CDK4 and CDK6. Secondary structure
elements for CDK2 and CDK6 are indicated
above and below the sequences; α helices are
shown as rectangles and β strands as arrows.
Conserved residues in all three molecules are
printed in bold and phosphorylation sites are
marked by asterisks. The CDK2 residues that
interact with v-cyclin in a model complex are
marked by filled triangles.
hCDK2:             MENFQKVEKIGEGTYGVVYKARN-KLTGEVVALKKIRLDTE---TEGVPSTA    48
hCDK4:           MATSRYEPVAEIGVGAYGTVYKARD-PHSGHFVALKSVRVPNGGGGGGGLPIST    53
hCDK6:    MEKDGLCRADQQYECVAEIGEGAYGKVFKARDLKNGGRFVALKRVRVQT---GEEGMPLST    58
hCDK2: IREISLLKELN---HPNIVKLLDVIHT-----ENKLYLVFEFLHQDLKKFMDASALTGIPLPLI   104
hCDK4: VREVALLRRLEAFEHPNVVRLMDVCATSRTDREIKVTLVFEHVDQDLRTYLDKAPPPGLPAETI   117
hCDK6: IREVAVLRHLETFEHPNVVRLFDVCTVSRTDRETKLTLVFEHVDQDLTTYLDKVPEPGVPTETI   122
hCDK2: KSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWY   168
hCDK4: KDLMRQFLRGLDFLHANCIVHRDLKPENILVTSGGTVKLADFGLARIYSYQM-ALTPVVVTLWY   180
hCDK6: KDMMFQLLRGLDFLHSHRVVHRDLKPQNILVTSSGQIKLADFGLARIYSFQM-ALTSVVVTLWY   185
hCDK2: RAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTS   232
hCDK4: RAPEVLLQS-TYATPVDMWSVGCIFAEMFRRKPLFCGNSEADQLGKIFDLIGLPPEDDWPRDVS   243
hCDK6: RAPEVLLQS-SYATPVDLWSVGCIFAEMFRRKPLFRGSSDVDQLGKILDVIGLPGEEDWPRDVA   248
hCDK2: MPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL 298
hCDK4: LP--RGAFPPRGPRPVQSVVPEMEESGAQLLLEMLTFNPHKRISAFRALQHSYLHKDEGHPE     303
hCDK6: LP--RQAFHSKSAQPIEKFVTDIDELGKDLLLKCLTFNPAKRISAYSALSHPYFQDLERCKENLD  301
hCDK6  SHLPPSQNTSELNTA   326
β1 β2 β3
β4 β5
β7 β8
α1 α2
α3
α4 α5
β1 β2 β3
α1 β4 β5 α2
α3 β6 β7 β8 αL12
α4 α5
α6 α7
α6 α7
αL14
**
*
Structure
p16INK4 have much lower kinase activity, possibly because
of p16INK4-induced structural distortions. As it is unlikely
that v-cyclin can compete with p16INK4 for CDK6 binding,
the lack of v-cyclin–CDK6 inhibition by p16INK4 may be
due to high affinity v-cyclin binding, which could stabilize
CDK6 in its active conformation.
Kinase activation
The kinase activity of v-cyclin–CDK6 complexes appears
to be orders of magnitude larger than those of cyclin-
D–CDK6 complexes [20]. From biochemical and struc-
tural studies of cyclin-A–CDK2 complexes, it is known
that full activation of kinase activity requires complex for-
mation with cyclin A and phosphorylation of Thr160 in
CDK2. Without this activating phosphorylation, kinase
activity is minimal [43]. Similarly, full activation of CDK6
by v-cyclin requires phosphorylation of the equivalent
Thr177 residue (JUJ, personal communication). The acti-
vating phosphorylation in CDK2 induces conformational
changes in the T loop and C-terminal lobe of CDK2, as
well as new packing interactions within CDK2 and with
cyclin A [27]. A modeled v-cyclin–CDK2 complex would
have many close interactions between v-cyclin and both
unphosphorylated and phosphorylated CDK2 residues in
the T loop and PSTAIRE helix (Figure 5b). As both the
PSTAIRE helix and T loop provide critical residues for
catalysis and substrate binding, it seems likely that 
v-cyclin binding to CDK6 could influence specific kinase
activity as well as substrate specificity by inducing confor-
mational changes in the T-loop region, or by contributing
directly to substrate binding. A clear understanding of
CDK6 activation by v-cyclin, however, will have to await
the structure determination of a v-cyclin–CDK6 complex.
Biological implications
Eucaryotic cell-cycle progression is tightly regulated by
cyclin-dependent kinases (CDKs). The activity of these
enzymes is controlled by several mechanisms including
complex formation with regulatory proteins called
cyclins. In higher eucaryotes, seven CDK and eight
cyclin classes have been identified. Mutations and over-
expression of cyclins and CDKs has been associated with
tumorigenesis and oncogenesis. Recently, virus-encoded
proteins with highest homology to type D cyclins have
been identified in two oncogenic herpesviruses. These
proteins may contribute to the transforming potential of
these viruses. Both viral cyclins (v-cyclins) have a strong
preference for CDK6, which is predominantly expressed
in lymphoid cells. The CDK6 complexes with v-cyclins
have higher specific activity than those with human
cyclins and are not inhibited by protein inhibitors of the
p21 family (eg. p27Kip1) or INK4 family.
The X-ray structure of a v-cyclin, reported here, is very
similar to that of human cyclin A, in spite of low
sequence identity. In a model complex of v-cyclin with
activated CDK2, the contact areas are comparable to
those in the cyclin-A–CDK2 complex with many
detailed interactions being conserved. Contacts between
v-cyclin and CDK2 that are too close or electrostatically
unfavorable may be more favorable in a complex with
CDK6 due to sequence differences, and may contribute
to the specificity of v-cyclin for CDK6.
The region of v-cyclin that is equivalent to the p27Kip1-
binding pocket of cyclin A shows significant changes in
the shape of the protein surface. In addition, sequence
changes between cyclin A and v-cyclin reduce the number
of possible hydrogen bonds between p27Kip1 and v-cyclin.
Together, these changes may explain the insensitivity of 
v-cyclin to inhibitors of the p21 family of inhibitors.
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Figure 7
Surface representation of the p27Kip1-binding pocket in (a) cyclin A
(green) and (b) the equivalent area in v-cyclin (blue). The surface areas
were calculated with a 1.7 Å probe. Part of the p27Kip1 inhibitor,
including residues 25–35, are shown as a CPK model with atoms in
standard colors. (The figure was made with the program INSIGHT II.)
A structural basis for the high activation of CDK6 by v-
cyclin is likely to involve catalytic and substrate-binding
residues from two key regions of CDK6: the PLSTIRE
helix and the T loop. v-Cyclin is likely to form many con-
tacts with these areas thereby influencing kinase activity
and possibly substrate specificity. A detailed description
of the activation process will require the structure deter-
mination of a v-cyclin–CDK6 complex.
Materials and methods
Expression, purification and crystallization of v-cyclin
HVS v-cyclin was cloned into the pQE-9 expression vector (Qiagen, San
Diego) as described previously [20] and transformed into Escherichia
coli strain DH5α(DE3), pACYC. The vector provides a non-cleavable 
N-terminal 6-His-tag, which was used for affinity purification. For protein
purification, E. coli were grown at 37°C to an OD600 of 1.0 and induced
at 22°C with 0.5 mM isopropyl-β-D-thiogalactosidase (IPTG) for 4 h.
Cells were harvested by centrifugation at 8000 g and resuspended in
25 mM Tris/HCl, 25% sucrose (pH 7.5) at 4°C before the addition of
lysozyme to a final concentration of 0.1 mg/ml. After incubation for
30 min, protease inhibitors (phenylmethylsulfonyl fluoride [PMSF; 1 mM],
aprotinin [8 µg/ml] and leupeptin [4 µg/ml]) and DNAse I (5 µg/ml) were
added and incubated for a further 30 min at 4°C. Cell lysis was com-
pleted by sonication, followed by centrifugation at 27000 g. Under these
conditions, about half of the expressed v-cyclin was soluble in the super-
natant. The supernatant was loaded onto a 5 ml Co2+-loaded iminodi-
acetic affinity column equilibrated in buffer A (20 mM sodium phosphate
pH 7.1, 200 mM NaCl, 10% glycerol). After washing the column with
buffer comprising 90% buffer A and 10% buffer B (20 mM sodium phos-
phate pH 7.2, 200 mM NaCl, 300 mM imidazole, 10% glycerol), protein
was eluted with a 25 ml gradient from 50% to 100% buffer B. Gradient
elution improved the purity of v-cyclin. Combined fractions from the Co2+
column were dialyzed against buffer C (25 mM Tris/HCl pH 8.4, 25 mM
NaCl, 2 mM EDTA, 4 mM dithiothreitol [DTT], 5% glycerol) overnight and
purified over a Source Q anion exchange column (Pharmacia) by elution
with a gradient from 0–40% buffer D (25 mM Tris/HCl pH 8.4, 1 M NaCl,
2 mM EDTA, 4 mM DTT, 5% glycerol) in ten column volumes. v-Cyclin
elutes as a well separated double or triple peak, of which only the major
component was collected for crystallization.
The protein aggregates and precipitates very easily, especially under low
salt conditions. As initial crystallization screens [44] showed small crystals
in high concentrations of phosphate buffer, we concentrated the protein in
0.15 M sodium/potassium phosphate pH 7.0, 2 mM EDTA, 10 mM DTT to
a concentration of 4.0–4.5 mg/ml. v-Cyclin was crystallized at 22°C in
sitting drops using the vapor diffusion technique. A 3 µl aliquot of protein
was combined with 1 µl precipitant and equilibrated against the precipi-
tant that was optimized to 0.8 M Na/K phosphate pH 7.0, 4% PEG 1500,
20 mM DTT. If crystals did not form within three to four days, the precipi-
tant concentration was raised slowly. v-Cyclin crystals are single block-
shaped crystals with average dimensions of 0.3 × 0.15 × 0.08 mm.
Data collection and processing
All data sets were collected from crystals flash-frozen in a nitrogen gas
stream following soaking in 1.0 M Na/K phosphate pH 7.0 with step-
wise increases in glycerol concentration to 30%. One native data set
was collected at the National Synchrotron Light Source in Brookhaven
at beamline X12B, using a MAR Research Imaging detector. A second
native data set and two derivative data sets were collected on a Rigaku
R-AXIS imaging plate mounted on a rotating-anode X-ray source. All
images were integrated and scaled using the HKL suite of programs
[45]. Further processing was carried out using programs from the
CCP4 package [30]. Data collection statistics are shown in Table 1.
Structure solution 
The v-cyclin structure was solved by a combination of molecular
replacement and MIR. Available structures of homologous cyclins were
used as models for molecular replacement [28] and optimized by omit-
ting longer loop regions and non-homologous sidechains. Phases from
the best molecular replacement solution, according to the highest cor-
relation coefficient of 49.5% for 15.0–4.0 Å data, were used for cross-
difference fourier with heavy-atom derivative data sets and for phase
combination with MIR phases. Refinement of heavy-atom parameters
and calculation of MIR phases to 4.0 Å were performed with
MLPHARE [46] (Table 1). MIR phases were combined with molecular
replacement phases using the program SIGMAA [30] and improved by
solvent flattening and histogram matching with the program DM [30].
Refinement and model building
The molecular replacement model of human cyclin A, comprising
residues 207–243, 251–342 and 352–400, was used as an initial
model for electron-density fitting with the program O [47]. Crystallo-
graphic refinement was performed using the programs X-PLOR 3.84
and, in later stages, a developmental version of the program CNS (AT
Brünger, personal communication) with a maximum likelihood target
function, a flat bulk-solvent correction, and low-resolution data to 20 Å
included. A subset (10%) of randomly selected structure-factor ampli-
tudes were excluded from automated refinement and used to compute
a free R factor (Rfree) [48] throughout the refinement.
Accession numbers
The final coordinates of v-cyclin have been deposited with the
Brookhaven Protein Data Bank with accession number 1BU2. 
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